TOPNews Release

News Release

  • RSS

2016

25/11/2016
Otsuka Joins UN Global Compact (PDF:176KB)
18/11/2016
Taiho and Meiji Announce the Launch of Bilanoa® Tablets 20 mg, an Oral Anti-allergy Drug in Japan (PDF:64KB)
28/9/2016
Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa® Tablets, an Oral Anti-allergy Drug in Japan
30/8/2016
UK’s NICE Recommends LONSURF® (trifluridine/tipiracil) As Treatment of Previously Treated Metastatic Colorectal Cancer - Taiho’s Partner Servier to Market LONSURF in UK - (PDF:240KB)
25/8/2016
New Drink-Type Gingyo-san (lonicerae and forsythia powder) Containing 10 Varieties of Herbal Medicine to Be Launched on August 25, 2016 Works for Early Symptoms of Common Cold Such As Sore Throat and Cough (PDF:149KB)
29/7/2016
Application for Additional Indications of Complicated Skin and Soft Tissue Infections (Including Diabetic Foot Infections) for ZOSYN®, an Injectable Antibiotic Combined with β-lactamase Inhibitor
31/5/2016
Otsuka Holdings Announces New,
Additional Certification Under “ISO 22301”,
the International Standard for Business Continuity Management (PDF:167KB)
10/5/2016
Taiho Pharmaceutical Forms Taiho Ventures to Foster Oncology Biotech Start-ups
28/4/2016
Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have New Treatment Option as LONSURF® (trifluridine/tipiracil) Receives EU Approval
11/4/2016
MSD and Taiho Enter into Co-Promotion Agreement in Japan for Pembrolizumab, MSD’s Immune Checkpoint Inhibitor (Anti-PD-1 Therapy) (PDF:148KB)
11/4/2016
Tiovita series to go on sale outside Japan Tiovita 3000 to Be Released in Hong Kong “Supporting the hard workers of Hong Kong”
1/4/2016
Taiho’s TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory
Metastatic Colorectal Cancer
15/3/2016
Taiho Pharmaceutical Announces Personnel Changes (PDF:76KB)
29/2/2016
CHMP Issues Positive Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
24/2/2016
Toray, Nanotheta, Taiho to Accelerate Business of Antiadhesive Material Based on Nano-scale Polymer Thin Film Technology (PDF:146KB)

Top of Page

2015

17/12/2015
Taiho and Meiji Enter Into a Co-marketing Agreement in Japan for TAC-202(bilastine), a Treatment for Allergic Disorders (PDF:555KB)
26/11/2015
NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent “Yondelis® IV Infusion”
13/11/2015
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
28/9/2015
Novel Antitumor Agent “Yondelis® IV Infusion” Approved in Japan for Treatment of Soft Tissue Sarcoma
24/9/2015
Taiho Pharmaceutical Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC)
1/9/2015
The First Pre-Meal Drink in the Solmack Series "Solmack 5 Herbal Digestive Support" Nationwide Launch in Japan on Monday, September 7
26/6/2015
ZOSYN® Receives Approval for the Additional Indication of Febrile Neutropenia
15/6/2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
1/6/2015
Support for modern people in the prime of life! Designated quasi-drug Tiovita Gold α (Alpha) mini-drink to be launched throughout Japan on June 22
14/5/2015
Results from Global Phase III Trial of TAS-102 (brand name in Japan: "Lonsurf® ") Published in The New England Journal of Medicine
20/3/2015
Lonsurf® Combination Tablet for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer Receives Approval in Japan for Partial Change in Indications
2/3/2015
Taiho Submits TAS-102 (brand name in Japan: "Lonsurf®") Marketing Authorization Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer
23/2/2015
Taiho Pharmaceutical Announces TAS-102 (brand name in Japan: "Lonsurf®") New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
5/1/2015
Taiho Pharmaceutical Receives Approval to Manufacture and Market ZOSYN® 4.5 for I.V. Infusion Bag, an Injectable Antibiotic Combined with β-Lactamase Inhibitor

Top of Page

2014

24/12/2014
Taiho Pharmaceutical Completes Submission of TAS-102 New Drug Application to the US Food and Drug Administration for the Treatment of Refractory Metastatic Colorectal Cancer
18/12/2014
Antitumor Agent "Abraxane®I.V. Infusion 100 mg" Approved for Additional Indication of Unresectable Pancreatic Cancer
21/10/2014
Taiho Pharmaceutical Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer
– Taiho Initiates Rolling NDA Submission for TAS-102 –
31/7/2014
Taiho Pharmaceutical Announces Termination of Phase III Clinical Trial of the Angiogenesis Inhibitor TSU-68 (orantinib) in Patients with Hepatocellular Carcinoma
25/7/2014
Phase III Clinical Study of S-1 in Patients with Advanced Hepatocellular Carcinoma Did Not Meet Its Primary Endpoint
23/7/2014
Taiho Pharmaceutical Invests US$ 30 Million in Remiges BioPharma Fund, LP to Foster Early Biotech Start-ups
2/7/2014
Application for the Additional Indication of Febrile Neutropenia for ZOSYN®, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
30/6/2014
Taiho Pharmaceutical Announces Results from TAS-102 Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
11/6/2014
Taiho Pharmaceutical Announces Personnel Changes (PDF:132KB)
4/6/2014
Data from Phase II Trial of ET-743 (trabectedin), a Novel Antitumor Agent, in Patients with Malignant Soft Tissue Sarcoma Presented at ASCO®
3/6/2014
Results of Phase III Clinical Study (SELECT BC) of TS-1 Treatment for Metastatic Breast Cancer Announced at ASCO®
23/5/2014
Anticancer Drug Lonsurf® Combination Tablet Receives NHI Reimbursement Price Listing and is Scheduled for Launch
12/5/2014
Taiho Oncology's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Global Phase III RECOURSE Trial in Refractory Metastatic Colorectal Cancer
22/4/2014
ET-743 (trabectedin), a Novel Antitumor Agent Meets Primary Endpoint of Progression Free Survival Prolongation in a Phase 2 Trial in Malignant Soft Tissue Sarcoma Patients
24/3/2014
Taiho's Lonsurf® (trifluridine and tipiracil hydrochloride) Tablets Approved in Japan for Treatment in Advanced Metastatic Colorectal Cancer
6/1/2014
Transfer of Astellas' Fermentation Research-Related Assets to Taiho Pharmaceutical (PDF:153KB)

Top of Page

2013

Top of Page

2012

30/11/2012
Announcement; Launch of 5-HT3 Receptor Antagonist Aloxi® I.V. infusion bag 0.75mg
28/9/2012
ZOSYN®, an Injectable Antibiotic Combination Product Receives an Approval for Peritonitis,
Intra-abdominal Abscess, Cholecystitis, and Cholangitis
18/9/2012
Clinical Trial (JASPAC01) of TS-1 for Resected Pancreatic Cancer
28/8/2012
Results of a Phase II Clinical Trial for the Novel Antitumor Agent TAS-102 Posted on the Electronic Edition of The Lancet Oncology
24/7/2012
Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti-Allergy Agent
11/7/2012
Business Partnership regarding Breakthrough Cancer Pain Reliever "OVF" (PDF:59KB)
22/6/2012
Launch of Histamine H2 Receptor Antagonist PROTECADIN® OD Tablets (Orally Disintegrating Tablet)
6/6/2012
Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)
31/5/2012
Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial
in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102
16/4/2012
Distributor change for Lentinan I.V. Infusion 1mg "Ajinomoto", an anti-tumor agent (PDF:57KB)
11/4/2012
Anti-Cancer Drug Teysuno® has been launched in the United Kingdom.
11/4/2012
Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Hong Kong
30/3/2012
Termination of co-development of a β3-adrenoceptor agonist (PDF:61KB)
21/3/2012
Anti-Cancer Drug Teysuno® has been launched in Sweden, Denmark, Norway and Finland
21/3/2012
Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Thailand
9/3/2012
Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis
1/3/2012
ABRAXANE® I.V. Infusion 100mg Application
Submitted for Approval of Additional Indications in Japan

Top of Page

2011

Top of Page

2010

Top of Page

2009

Top of Page

2008

1/10/2008
Basic agreement reached with Nippon Shinyaku for the collaborative development and marketing of a new antipruritic agent (code NS-141)
1/10/2008
Domestic manufacture of downsized Uzel (calcium folinate) 25 mg tablets to be started soon
1/10/2008
Autumn 2008 version TV commercial for Tiovita Drink is aired
30/9/2008
Zosyn, a new injectable combination antibiotic of beta-lactamase inhibitor and penicillin domestically launched on October 1
30/9/2008
Taiho Pharmaceutical collaborates with and supports the Japan Pink Ribbon Campaign for this year
29/9/2008
46th fiscal-year (07/2007- 06/2008) report is released
22/9/2008
New website contents to promote medical check-ups for breast cancer are released
2/9/2008
The antipsoriatic ethical drugs, Urepearl-Plus Lotion 10 and Urepearl-Plus Cream are launched on September 3
20/8/2008
8th Oncology Media Seminar is held: Main topic - Current therapyfor breast cancer
25/7/2008
Notice: Three Otsuka group companies (Otsuka Pharmaceutical Factory, Otsuka Warehouse, and Taiho Pharmaceutical) are reorganized as wholly-owned direct subsidiaries
18/7/2008
License agreement with Sanofi-Aventis on TS-1 is terminated
18/7/2008
Results of a randomized comparative phase 3 study of S-1 in advanced/recurrent gastric cancer become available
16/7/2008
Notice: Acquisition of production/distribution license for Zosyn, a new injectable combination antibiotic of beta-lactamase inhibitor and penicillin
24/6/2008
Summer 2008 version TV commercial for Tiovita Drink is aired
7/4/2008
7th Oncology Media Seminar is opened: Main topic - Gastric cancer: Clinical studies of oral anti-gastric cancer agents and guidelines for the treatment of gastric cancer
25/3/2008
Results of a randomized comparative study of S-1 monotherapy compared to S-1 with cisplatin (SPIRITS trial) in advanced/recurrent gastric cancer is published in Lancet Oncology: New standard therapy for advanced gastric cancer anticipated
18/1/2008
Spring 2008 version TV commercial for Tiovita Drink is aired
Get ADOBE READER

To view PDF contents, you need the latest version of the Adobe Reader.


Top of Page